NASDAQ:IRIX IRIDEX (IRIX) Stock Price, News & Analysis $2.05 +0.06 (+3.02%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.03▼$2.0950-Day Range$1.97▼$2.7052-Week Range$1.31▼$3.65Volume48,187 shsAverage Volume32,625 shsMarket Capitalization$33.31 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get IRIDEX alerts: Email Address IRIDEX MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside2.4% Downside$2.00 Price TargetShort InterestBearish2.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.49) to ($0.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.12 out of 5 starsComputer And Technology Sector603rd out of 612 stocksElectromedical Equipment Industry22nd out of 22 stocks 1.0 Analyst's Opinion Consensus RatingIRIDEX has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIRIDEX has only been the subject of 1 research reports in the past 90 days.Read more about IRIDEX's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.74% of the float of IRIDEX has been sold short.Short Interest Ratio / Days to CoverIRIDEX has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in IRIDEX has recently decreased by 2.62%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIRIDEX does not currently pay a dividend.Dividend GrowthIRIDEX does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IRIX. Previous Next 1.8 News and Social Media Coverage News SentimentIRIDEX has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 2 news articles for IRIDEX this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added IRIDEX to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IRIDEX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of IRIDEX is held by insiders.Percentage Held by InstitutionsOnly 20.10% of the stock of IRIDEX is held by institutions.Read more about IRIDEX's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IRIDEX are expected to grow in the coming year, from ($0.49) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IRIDEX is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IRIDEX is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIRIDEX has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IRIDEX's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...Click here to see how >>> About IRIDEX Stock (NASDAQ:IRIX)IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.Read More IRIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRIX Stock News HeadlinesJuly 21, 2024 | americanbankingnews.comIRIDEX (NASDAQ:IRIX) Now Covered by StockNews.comJuly 17, 2024 | americanbankingnews.comIRIDEX Co. (NASDAQ:IRIX) Short Interest UpdateJuly 27, 2024 | Stansberry Research (Ad)Former Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.May 22, 2024 | finance.yahoo.comIRIDEX Corporation (IRIX)May 19, 2024 | msn.comIRIDEX Corporation (NASDAQ:IRIX) Q1 2024 Earnings Call TranscriptMay 19, 2024 | uk.investing.comEarnings call: IRIDEX reports Q1 2024 revenue decline, ongoing strategic reviewMay 15, 2024 | finance.yahoo.comIRIDEX Corp (IRIX) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...May 14, 2024 | investorplace.comIRIX Stock Earnings: Iridex Misses EPS, Misses Revenue for Q1 2024July 27, 2024 | Stansberry Research (Ad)Former Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.May 14, 2024 | globenewswire.comIridex Reports First Quarter 2024 Financial ResultsMay 14, 2024 | finance.yahoo.comEven after rising 11% this past week, IRIDEX (NASDAQ:IRIX) shareholders are still down 59% over the past three yearsMay 8, 2024 | finance.yahoo.comIridex to Report First Quarter 2024 Financial Results on May 14, 2024March 28, 2024 | benzinga.comIridex: Q4 Earnings InsightsMarch 28, 2024 | seekingalpha.comIridex's Strategic Review Process Should Bear Fruit 'Soon'March 27, 2024 | finanznachrichten.deIRIDEX Corporation: Iridex Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 27, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Iridex (IRIX) and Keros Therapeutics (KROS)March 27, 2024 | finance.yahoo.comIRIDEX Corporation (NASDAQ:IRIX) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | washingtonpost.comIridex: Q4 Earnings SnapshotSee More Headlines Receive IRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:IRIX CUSIPN/A CIK1006045 Webwww.iridex.com Phone(650) 940-4700Fax650-940-4710Employees120Year Founded1989Price Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside-1.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,570,000.00 Net Margins-21.92% Pretax Margin-21.69% Return on Equity-105.42% Return on Assets-31.18% Debt Debt-to-Equity RatioN/A Current Ratio1.72 Quick Ratio1.03 Sales & Book Value Annual Sales$51.87 million Price / Sales0.64 Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book3.45Miscellaneous Outstanding Shares16,250,000Free Float15,245,000Market Cap$33.07 million OptionableOptionable Beta0.83 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. David I. Bruce (Age 65)President, CEO & Director Comp: $397.19kMr. Fuad Ahmad (Age 54)Interim Chief Financial Officer Comp: $356.83kMr. Patrick Mercer (Age 52)Chief Operating Officer Comp: $365.85kMs. Leigh SalvoHead of Investor RelationsKey CompetitorselectroCoreNASDAQ:ECORNuwellisNASDAQ:CHFSRockwell MedicalNASDAQ:RMTIFONARNASDAQ:FONRVivani MedicalNASDAQ:VANIView All CompetitorsInstitutional OwnershipPerkins Capital Management Inc.Bought 5,200 shares on 5/10/2024Ownership: 0.279%AMH Equity LtdBought 60,400 shares on 5/7/2024Ownership: 2.809%View All Institutional Transactions IRIX Stock Analysis - Frequently Asked Questions How have IRIX shares performed this year? IRIDEX's stock was trading at $2.81 at the beginning of the year. Since then, IRIX stock has decreased by 27.0% and is now trading at $2.05. View the best growth stocks for 2024 here. How were IRIDEX's earnings last quarter? IRIDEX Co. (NASDAQ:IRIX) issued its quarterly earnings results on Tuesday, May, 14th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.09. The medical equipment provider earned $11.76 million during the quarter, compared to analyst estimates of $12 million. IRIDEX had a negative trailing twelve-month return on equity of 105.42% and a negative net margin of 21.92%. What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO? 7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees. How do I buy shares of IRIDEX? Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of IRIDEX own? Based on aggregate information from My MarketBeat watchlists, some other companies that IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Genocea Biosciences (GNCA) and Idera Pharmaceuticals (IDRA). This page (NASDAQ:IRIX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IRIDEX Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share IRIDEX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
